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Characterization and Proteome of 
Circulating Extracellular Vesicles as 
Potential Biomarkers for NASH
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Nonalcoholic fatty liver disease (NAFLD) is currently one of most common forms of chronic liver disease globally. 
NAFLD represents a wide spectrum of liver involvement from nonprogressive isolated steatosis to nonalcoholic stea-
tohepatitis (NASH), characterized by liver necroinflammation and fibrosis and currently one of the top causes of end-
stage liver disease and hepatocellular carcinoma. At present, there is a lack of effective treatments, and a central barrier 
to the development of therapies is the requirement for an invasive liver biopsy for diagnosis of NASH. Discovery of 
reliable, noninvasive biomarkers are urgently needed. In this study, we tested whether circulating extracellular vesicles 
(EVs), cell-derived small membrane-surrounded structures with a rich cargo of bioactive molecules, may serve as reli-
able noninvasive “liquid biopsies” for NASH diagnosis and assessment of disease severity. Total circulating EVs and 
hepatocyte-derived EVs were isolated by differential centrifugation and size-exclusion chromatography from serum 
samples of healthy individuals, patients with precirrhotic NASH, and patients with cirrhotic NASH. EVs were fur-
ther characterized by flow cytometry, electron microscopy, western blotting, and dynamic light scattering assays before 
performing a proteomics analysis. Our findings suggest that levels of total and hepatocyte-derived EVs correlate with 
NASH clinical characteristics and disease severity. Additionally, using proteomics data, we developed understandable, 
powerful, and unique EV-based proteomic signatures for potential diagnosis of advanced NASH. Conclusion: Our study 
shows that the quantity and protein constituents of circulating EVs provide strong evidence for EV protein–based liq-
uid biopsies for NAFLD/NASH diagnosis. (Hepatology Communications 2020;4:1263-1278).
Nonalcoholic fatty liver disease (NAFLD) has evolved to represent the most common cause of chronic liver disease globally.(1) Today, 
NAFLD is a leading indication for liver transplanta-
tion and a major etiology for hepatocellular carcinoma 
(HCC) in the United States.(2-4) NAFLD is charac-
terized by the excess accumulation of lipids within 
the liver, typically in individuals with the metabolic 
syndrome, which encompasses obesity, insulin resis-
tance, and dyslipidemia. The spectrum of NAFLD 
ranges from isolated steatosis, which has a benign 
nonprogressive course, to nonalcoholic steatohepati-
tis (NASH), which is characterized by the presence 
of hepatic necroinflammation and hepatocyte bal-
looning and is associated with fibrosis progression 
and pathological angiogenesis.(5,6) Although patients 
Abbreviations: ASGPR1, asialoglycoprotein receptor 1; AUROC, area under the receiver operating characteristic curve; CI, conf idence interval; 
ELF, Enhanced Liver Fibrosis; EV, extracellular vesicle; FC, fold change; FITC, fluorescein isothiocyanate; HCC, hepatocellular carcinoma; HVPG, 
hepatic venous pressure gradient; ICAM2, intercellular cell adhesion molecule 2; IL27RA, interleukin-27RA; kTSP, k top scoring pair; NAFLD, 
nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, nonalcoholic steatohepatitis; RGMA, repulsive guidance molecule A precursor; 
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with NAFLD may not develop NASH, patients with 
advanced NASH likely develop fibrosis and cirrhosis, 
end-stage liver disease, and HCC. NASH is currently 
a leading cause of end-stage liver disease and HCC 
in the United States, and reliable, surrogate diagnostic 
biomarkers for advanced NASH are urgently needed.(7) 
There is currently a lack of effective treatments, and 
great efforts are underway to develop pharmacological 
interventions for patients with NASH and fibrosis. 
At present, the only reliable method of differentiating 
fibrotic precirrhotic NASH from cirrhotic NASH is 
liver biopsy. However, this procedure is invasive and 
prone to complications such as bleeding,(8) is associ-
ated with sampling variability and limited represen-
tation of the whole liver (only 1/50,000 of the liver 
volume), is difficult to repeat to monitor changes in 
liver injury over time, and is associated with under-
estimation of disease severity. With the anticipated 
development of drug therapies for NASH, noninvasive 
alternatives to liver biopsy, to identify those patients 
who require intervention and follow these patients to 
monitor therapeutic responses, are urgently needed.(9) 
In this study, we evaluated the ability of circulating 
extracellular vesicles (EVs)(10) and their unique protein 
composition as noninvasive biomarkers for diagno-
sis and potential assessment of prognosis in patients 
with advanced NASH compared to healthy control 
subjects. Circulating EVs are cell-derived, nanosize 
and microsize membrane–surrounded structures con-
taining a specific cargo from the cell of origin. EVs 
can be detected abundantly in several body fluids,(11) 
emphasizing their potential utility as noninvasive liq-
uid biopsies.(12) We previously showed that in exper-
imental models of NASH, liver and blood levels of 
EVs are increased and correlate with changes in liver 
histology.(13) An in-depth characterization of the EV 
cargo through proteomic analysis also identified a 
signature that reliably differentiates NASH animals 
from controls.(13) In this human study we isolated 
circulating EVs from healthy control subjects, histo-
logically confirmed patients with precirrhotic NASH, 
and patients with cirrhotic NASH. After a complete 
characterization of EV structural features, we showed 
that differences in the quantity and protein constitu-
ents of circulating EVs enable the differentiation of 
patients with NASH from healthy control individu-
als, as well as patients with precirrhotic NASH from 
patients with cirrhotic NASH.
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Materials and Methods
patient samples
Baseline serum samples were collected from 25 
patients with precirrhotic NASH with F3 fibrosis and 
25 patients with cirrhotic NASH with F4 fibrosis, 
who participated in phase 2 randomized trials eval-
uating the safety and efficacy of simtuzumab ver-
sus placebo (Clinicaltrials.gov NCT01672866 and 
NCT01672879).(14) As controls, the serum from 25 
healthy subjects who participated in pharmacokinetics 
and phase 1 trials were evaluated. Further information 
can be found in the Supporting Information.
stuDy assessments
Liver histologic assessments were performed as 
previously described.(14) Further information on liver 
biopsies assessments is provided in the Supporting 
Information.
isolation anD 
CHaRaCteRiZation oF 
CiRCulating eXtRaCellulaR 
VesiCles
Circulating EVs were isolated from serum sam-
ples by differential centrifugation and by size exclu-
sion chromatography, as previously described.(15) 
Circulating EV identification and quantitation was 
performed using the BD LSRII Flow Cytometer 
System (BD Biosciences, San Jose, CA), and the data 
were analyzed using FlowJo software (TreeStar Inc., 
Ashland, OR), as previously described.(13) Further 
information on EV isolation and characterization is 
provided in the Supporting Information.
pRotein isolation anD 
WesteRn Blotting
Purified circulating EV proteins were extracted 
through five freeze/thaw cycles, which result in greater 
concentration of extracts and enrichment of low abun-
dant proteins. Protein concentration was determined 
by micro BCA protein assay kit (catalog #23235; 
Thermo Scientific, Waltham, MA), according to the 
manufacturer’s instructions. Further information can 
be found in the Supporting Information.
somascan pRoteomiCs aRRay 
anD Data analysis
The protein cargoes of EVs were determined in 
purified isolated circulating EVs from healthy con-
trols,(16) patients with precirrhotic (F3) NASH, 
and patients with cirrhosis (F4) due to NASH by 
SOMAscan protein array (SomaLogic, Boulder, 
CO), which included 1,345 unique proteins. 
Further information can be found in the Supporting 
Information.
DeVelopment oF a 
RepRoDuCiBle eV  
pRotein–BaseD signatuRe
To explore prognostic EV protein markers for 
NASH, we trained and validated a parameter-free 
classifier called “k top scoring pair” (kTSP)(17,18) 
using a training data set and a validation data set. 
Further information can be found in the Supporting 
Information.
eValuation oF tHe 
peRFoRmanCe oF ktsp 
ClassiFiCation
The performance of the classification is eval-
uated by the area under the receiver operating 
characteristic curve (AUROC) using the kTSP 
classifier built with training data and the threshold 
selected to achieve the best classification accuracy. 
Further information can be found in the Supporting 
Information.
paiRWise CompaRisons oF eVs 
in a ValiDation stuDy
Pairwise comparisons were generated for the top 
expressed proteins in the validation study comparing 
all three cohorts. Further information can be found in 
the Supporting Information.
statistiCal analysis
Excluding the proteomics data, which were ana-
lyzed differently as reported previously, all other data 
were expressed as the mean ± SD unless otherwise 
indicated. Differences among three or more groups 
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were compared by a nonparametric Kruskal-Wallis 
analysis of variance test. Further information on the 
statistical analysis can be found in the Supporting 
Information.
Results
CiRCulating eVs Can 
Be iDentiFieD anD 
CHaRaCteRiZeD in tHe seRa 
oF nasH patients
Circulating EVs isolated from plasma and serum 
have been proposed as “liquid biopsies” for several 
diseases.(12,19-22) Tumor-EVs isolated from the sera 
of patients with tumor glioblastoma showed robust 
performance in providing diagnostic information and 
aid in therapeutic decisions for patients with cancer 
through a blood test.(10,23) Based on these reports, 
we investigated whether hepatocyte-derived EVs 
could serve as prognostic and diagnostic biomarkers 
for advanced NASH. To address this hypothesis, we 
isolated circulating EVs from patients with precir-
rhotic NASH (n = 25), patients with cirrhotic NASH 
(n  =  25), and healthy control subjects (n  =  25), as 
detailed in Table 1. Total circulating EVs were isolated 
and purified by differential centrifugation followed by 
size-exclusion chromatography, to separate EVs from 
circulating serum proteins, contaminants and lipopro-
teins, particularly high-density lipoproteins (Fig. 1A). 
Pure circulating EVs from each group were further 
characterized and quantified. We first grouped all 
NASH samples and compared the EV levels with those 
in healthy controls. Flow cytometry analyses identi-
fied a significantly higher number of total calcein– 
fluorescein isothiocyanate (FITC)+ circulating EVs 
in NASH samples compared with healthy controls 
(Fig. 1B). The average circulating EV size did not 
differ between NASH and healthy control samples 
(Fig. 1C). EVs were further characterized using trans-
mission electron microscopy (TEM). TEM identified 
a large heterogeneous population of circulating EVs 
in both NASH and healthy control samples, and no 
specific EV morphological features were found to be 
present among study groups (Fig. 1D). Previously 
established circulating EV protein markers(24) were 
identified through western blot analysis and included 
Alix, CD63, and TSG101 (tumor susceptibility gene 
101) (Fig. 1E). TSG101 (ESCRT-I protein tumor 
susceptibility gene 101) plays a role in EV synthe-
sis and secretion,(25) particularly by damaged cells, 
which normally secrete higher levels of EVs. Our data 
indicate that in patients with advanced fibrosis due 
to NASH, EVs are secreted into the blood stream 
and can be isolated and characterized based on their 
molecular and physical properties.
leVels oF HepatoCyte-
DeRiVeD eVs aRe assoCiateD 
WitH nasH CHaRaCteRistiCs 
anD CoRRelate WitH Disease 
seVeRity
To determine whether the amount of total cir-
culating EVs could discriminate between different 
stages of NASH, we measured EV levels separately 
in both the precirrhotic NASH cohort as well as the 
cirrhotic NASH cohort, and we compared the results 
with the healthy control samples. Our data show that 
the median level of EVs was not significantly greater 
in patients with precirrhotic NASH compared with 
taBle 1. Baseline CHaRaCteRistiCs oF tHe 
stuDy population
Total (n = 50)
Demographics Age, years 55 (48-58)
Female 68% (34)
Body mass index, kg/m2 33 (29-37)
Liver 
biochemistry
Alanine aminotransferase, U/L 40 (29-73)
Alkaline phosphatase, U/L 78 (65-106)
Gamma-glutamyl transferase, U/L 59 (31-108)
Bilirubin, mg/dL 0.5 (0.4-0.7)
INR 1.1 (1.0-1.1)
Platelets, ×103/µL 171 (137-240)
MELD 7 (6-8)
Fibrosis markers NAFLD Fibrosis Score 0.14 (−0.95 to 1.22)
FibroSURE 0.43 (0.22-0.77)
ELF Test 10.0 (9.3-10.7)
Histology NAS ≥ 4 73% (36/49)
Cirrhosis (Ishak 5-6) 50% (25)
Portal pressure HVPG 11.5 (8.5-15.5)
CSPH (HVPG ≥ 10 mm Hg) 52% (13)
Note: All data are presented as the median (interquartile range) or 
percentage (n). HVPG was measured only in subjects with cirrhosis.
Abbreviations: CSPH, clinically significant portal hypertension; 
INR, international normalized ratio; and MELD, Model for End-
Stage Liver Disease.
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Fig. 1. Isolation, detection, and characterization of circulating EVs in serum samples of patients with NASH. (A) Flow chart of circulating 
EV isolation. (B) Number of calcein/FITC+ circulating EVs detected by flow cytometry in healthy controls (n = 11) or liver biopsy–proven 
patients with advanced NASH (n = 50). (C) Mean size(38) of circulating EVs measured by dynamic light scattering. (D) Representative 
TEM microphotographs of circulating EVs. (E) Representative western blots of EV markers Alix, CD63, and TSG101 in healthy controls 
and patients with advanced NASH. Values represent mean ± SD. Kruskal-Wallis test with post hoc Mann-Whitney U test and Bonferroni 
correction were used for statistical analysis. Abbreviation: HC, healthy control.
Hepatology CommuniCations, september 2020POVERO ET AL.
1268
healthy controls, whereas the median EV level was 
significantly higher in patients with cirrhotic NASH 
compared with healthy controls (Fig. 2A). This sug-
gests that disease severity and progression are associ-
ated with greater EV secretion from damaged cells. 
Compared to total EVs, tissue-specific or cell-specific 
circulating EVs may represent a stronger indicator of 
a disease pathophysiological status and may provide 
important and unique information on the injured tis-
sue or a specific pathophysiological process. For this 
reason, we examined two hepatocyte-specific markers 
in circulating EVs: the bile acyl–coenzyme A synthe-
tase (SLC27A5) and the asialoglycoprotein receptor 
1 (ASGPR1). Our data indicate that approximately 
20% of total circulating EVs expressed hepatocyte- 
specific markers. Median levels of SLC27A5-positive 
EVs were 3-4-fold greater in subjects with NASH 
compared to healthy controls; no significant differ-
ence was noted between the two NASH cohorts 
(Fig. 2B). Expression of SLC27A5 is up-regulated 
in fat-laden hepatocytes, as this enzyme plays a cru-
cial role in fatty acid uptake, elongation, and syn-
thesis. On the other hand, SLC27A5 expression is 
down-regulated during the progression from NASH 
to cirrhosis, likely as a result of fat loss occurring 
during the late stage of the disease.(26) These find-
ings suggest that SLC27A5 may be a specific marker 
of fat-laden hepatocyte-EVs of NAFLD and NASH 
livers, but not of hepatocyte-EVs of cirrhotic liv-
ers, which instead contain ASGPR1, whose expres-
sion is independent of fatty acid homeostasis. Levels 
of ASGPR1-positive EVs increased with disease 
severity, almost doubling in precirrhotic NASH and 
increasing three-fold in cirrhotic NASH compared 
with healthy controls (Fig. 2C). To further test the 
diagnostic ability of hepatocyte-derived EVs, we 
determined associations between the number of EVs 
with key serological, histological, and hemodynamic 
features of disease severity, including liver biochem-
istries, NAFLD activity score (NAS), fibrosis stage, 
hepatic collagen content, α-smooth muscle actin 
expression by morphometry, serum fibrosis markers, 
and in patients with cirrhotic NASH, the hepatic 
venous pressure gradient (HVPG). Although the 
number of EVs did not correlate with demographic 
features, liver biochemistry, NAFLD activity score, 
fibrosis markers, HVPG or Model for End-Stage 
Liver Disease score (data not shown), the number of 
hepatocyte-derived, circulating EVs correlated with 
fibrosis stage, FibroTest, Enhanced Liver Fibrosis 
(ELF) test, NAFLD Fibrosis Score, bilirubin, and 
platelet count (Table 2). Moreover, a statistically signif-
icant correlation between the number of hepatocyte- 
derived circulating EVs and values of HVPG in 
patients with cirrhosis was observed (Fig. 2E). Indeed, 
patients with clinically significant portal hypertension 
(HVPG ≥ 10  mmHg) had more hepatocyte-derived 
circulating EVs than patients with HVPG below 
10  mmHg (Fig. 2D). We also tested the ability of 
hepatocyte-derived EVs to accurately and noninva-
sively predict clinically significant portal hypertension 
in patients with cirrhotic NASH, as an alternative 
to invasive HVPG measurement. Our analysis indi-
cates that the hepatocyte-derived EV cutoff of at least 
668  EVs/µL serum exhibits sensitivity of 92% and 
specificity of 75% for differentiating patients with 
and without clinically significant portal hypertension 
(AUROC: 0.79; 95% confidence interval [CI]: 0.589-
0.988) (Fig. 2F). In summary, these findings indicate 
that a subpopulation of circulating EVs identified in 
patients with NASH are released by hepatocytes and 
that that hepatocyte-specific EVs strongly correlate 
with clinical features of NASH severity.
pRoteomiCs analysis oF 
CiRCulating eVs iDentiFies 
DiFFeRentially eXpResseD 
pRoteins in HealtHy 
ContRols, pReCiRRHotiC 
nasH, anD CiRRHotiC nasH 
samples
Extensive published studies have demonstrated 
the presence of abundant proteins, among other bio-
active molecules, encapsulated in EVs.(27) Analyzing 
EV protein composition may identify disease-specific 
or disease stage–specific proteins highly enriched in 
EVs that may provide protein signatures for disease 
diagnosis. As a consequence, we decided to determine 
the circulating EV proteome, applying an unsuper-
vised comprehensive proteomics approach. Lysates 
of purified circulating EVs isolated from seven ran-
domly selected healthy control, precirrhotic NASH, 
and cirrhotic NASH samples were used for an ini-
tial discovery study using the SOMAscan protein 
array (SomaLogic, Boulder, CO), which included 
1,345 unique proteins. The results of this discovery 
Hepatology CommuniCations, Vol. 4, no. 9, 2020 POVERO ET AL.
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study identified proteins that were up-regulated or 
down-regulated uniquely in each of the three cohorts 
and other proteins that overlapped between two or 
more groups. Multiple comparisons of the differen-
tially expressed proteins (DEPs) in the three groups 
identified 78 up-regulated and 65 down-regulated 
proteins in precirrhotic NASH EVs when com-
pared with healthy control EVs, while we identified 
61 up-regulated and 108 down-regulated unique 
proteins in precirrhotic NASH EVs compared with 
cirrhotic NASH EVs (Fig. 3A). Oppositely, we iden-
tified 116 up-regulated and 129 down-regulated pro-
teins in cirrhotic NASH EVs compared with healthy 
control EVs, and 43 up-regulated and 18 down- 
regulated proteins in cirrhotic NASH EVs compared 
with precirrhotic NASH EVs (Fig. 3B). An unsu-
pervised hierarchical clustering analysis of the top 50 
DEPs with adjusted P value of 0.05 identified distinct 
and unique protein expression patterns particularly 
between healthy controls and cirrhotic NASH circu-
lating EVs, suggesting that the protein composition of 
EVs is strongly associated with the severity of NASH 
(Fig. 3C). To graphically display all statistically sig-
nificant circulating EV proteins identified in cirrhotic 
NASH EVs, volcano plots −log10(adj. P value) versus 
log2 fold-change of EV proteins in cirrhotic NASH 
versus precirrhotic NASH (Fig. 4A) and in cirrhotic 
NASH versus healthy controls (Fig. 4B) were con-
structed using a corrected P value of 0.05 as thresh-
old. Points above the nonaxial horizontal line indicate 
a EV-protein P value greater than 0.005, which were 
down-regulated if on the left of the nonaxial vertical 
red line or up-regulated if on the right of the nonax-
ial vertical green line. Five proteins demonstrated a 
0.2 or greater fold change (FC) in cirrhotic NASH 
versus precirrhotic NASH circulating EVs, whereas 
10 proteins demonstrated a 0.2 or greater FC in cir-
rhotic NASH versus healthy control circulating EVs. 
Particularly interesting is the up-regulation of von 
Willebrand factor (vWF) in cirrhotic NASH circulat-
ing EVs versus healthy controls. Even when below the 
P-value threshold of 0.005 used for this analysis, vWF 
demonstrated a 2-FC increase in cirrhotic NASH cir-
culating EVs registering a P value greater than 0.05. 
This protein is secreted primarily by endothelial cells 
and is strongly increased in serum of patients with cir-
rhosis. These findings may suggest a potential form of 
secretion of vWF by endothelial cells through EVs. 
We then wanted to identify distinct clusters of circu-
lating EV proteins that could clearly distinguish the 
NASH patients from the healthy individuals. For this 
reason, we performed unsupervised hierarchical anal-
yses of the top 50 differentially expressed proteins in 
cirrhotic NASH versus precirrhotic NASH or healthy 
control circulating EVs (Fig. 4C,D). Our proteom-
ics data suggest that circulating EVs carry specific 
proteins that may provide disease and disease stage– 
specific multiprotein-based signatures that may be use-
ful for diagnosis and potentially prognosis of NASH.
taBle 2. CoRRelation BetWeen HepatoCyte-
DeRiVeD CiRCulating eVs anD nasH-RelateD 
CliniCal VaRiaBles
Variable Spearman Correlation (ρ) P Value
Fibrosis stage 0.28 0.048
NAFLD Fibrosis Score 0.29 0.047
FibroSURE 0.31 0.037
ELF test 0.28 0.056
NAS 0.05 0.737
Bilirubin, mg/dL 0.26 0.066
Platelets, ×103/µL −0.38 0.006
HVPG, mm Hg 0.4 0.047
Note: Levels of ASGPR1+ circulating EVs as indication of 
hepatocyte-specific EVs were correlated with NASH clinical varia-
bles. The associations were determined using Spearman correlations 
and Mann-Whitney U tests.
Fig. 2. Levels of hepatocyte-specific circulating EVs correlate with NASH severity. (A) Number of calcein/FITC+ circulating EVs in 
healthy controls, patients with precirrhotic NASH, and patients with cirrhotic NASH detected by flow cytometry. (B,C) Flow cytometry 
analysis of hepatocyte-specific EVs either positive for hepatocyte marker SLC27A5 or ASGPR1. (D) Number of hepatocyte-specific 
circulating EVs in individuals with cirrhotic NASH with HVPG lower or greater than 10 mmHg, as indication of clinically significant 
portal hypertension. (E) Spearman correlation between hepatocyte-specific circulating EVs and HVPG levels. (F) AUROC curve for 
hepatocyte-derived EVs for diagnosis of portal hypertension in patients with cirrhotic NASH. Hepatocyte-EV count of 668 EVs/ µL or 
higher serum showed sensitivity of 92% and specificity of 75% for differentiating patients with clinically significant portal hypertension 
from patients with no clinically relevant portal hypertension (AUROC: 0.79; 95% CI: 0.589-0.988). Kruskal-Wallis test with post hoc 
Mann Whitney U test and Bonferroni correction were used for statistical analysis. Abbreviations: HC, healthy control; ROC, receiver 
operating characteristic.
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Fig. 3. Analysis of circulating EVs proteome by SOMAScan protein array in all three cohorts. (A) Venn diagram of differentially 
expressed EV proteins in patients with precirrhotic NASH versus healthy controls or patients with cirrhotic NASH. (B) Venn diagram of 
differentially expressed EV proteins in patients with cirrhotic NASH compared with healthy controls or patients with precirrhotic NASH. 
A cutoff of adjusted P value of 0.01 was used for both Venn diagrams. (C) Unsupervised hierarchical clustering analysis of the top 50 
differentially expressed circulating EV proteins in patients with cirrhotic NASH versus patients with precirrhotic NASH versus healthy 
controls (n = 7/group). The top 50 proteins listed on the heat map were selected based on the adjusted P value of 0.05 from the cirrhotic 
NASH versus healthy controls comparison. Mean and SD of all three groups were used to normalize the expression value. The closer the 
color is to bright blue, the lower the expression, whereas the closer the color is to bright red, the higher the expression.
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Fig. 4. Analyses of most abundant circulating EV proteins in paired comparisons. Volcano plots illustrating significantly differentially 
abundant EV-proteins in patients with cirrhotic NASH versus patients with precirrhotic NASH (A) and patients with cirrhotic NASH 
versus healthy controls (n = 7/group) (B). The -log10 (adjusted P value) is plotted against the log2 fold-change. The nonaxial vertical blue 
line denotes no effect in protein expression; green line denotes +0.2-fold change; and the red line denotes −0.2-fold change. The nonaxial 
black horizontal line denotes P value greater than 0.005, which is out of the significance threshold (before logarithmic transformation). 
Unsupervised hierarchical clustering analysis of the top 50 differentially expressed circulating EV proteins in patients with cirrhotic 
NASH versus patients with precirrhotic NASH (C) and in patients with cirrhotic NASH versus healthy controls (n = 7/group) (D). An 
adjusted P value of 0.05 was used to generate the heat maps. The closer the color is to bright blue, the lower the expression, whereas the 
closer the color is to bright red, the higher the expression.
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DeVelop RepRoDuCiBle 
signatuRe anD 
DiagnostiC test FoR nasH 
tHRougH ValiDation 
anD RepRoCessing oF 
CiRCulating eV pRoteomiCs 
Data
Currently, liver biopsy remains the gold standard 
for diagnosis of NASH despite its invasive nature, 
potential complications, and cost. Importantly, identi-
fication and validation of reliable diagnostic and prog-
nostic biomarkers for NASH are urgently needed. A 
major hurdle in translating biomarker research stud-
ies into clinically useful assays is lack of reproducibil-
ity and rigorous criteria to report potential NASH 
biomarkers. For these reasons, in this study we aim 
to identify EV protein–based signatures for potential 
diagnosis and prognosis of advanced NASH, based 
on several two-protein comparisons. Specifically, our 
goal was to provide a transparent method through 
which a proteomics-based NASH stage predictor 
might be developed from training data and evalu-
ated on independent test data with sufficient detail 
and documentation to allow the full process to be 
replicated by other researchers. To address this goal, 
we adopted an extension of kTSP to develop under-
standable and powerful EV-based proteomics signa-
tures.(17) Using the top 100 proteins as input, 3 pairs 
were selected for the advanced NASH versus healthy 
controls comparison (Fig. 5A), and 12 pairs were 
selected for the precirrhotic NASH versus cirrhotic 
NASH comparison, from 2 to 50 pairs (Fig. 5C). To 
better illustrate which feature pairs are promising for 
classification among three combinations of precir-
rhotic NASH, cirrhotic NASH or healthy controls, 
we generated the corresponding heat maps (Fig. 
5A,C). Analyses of the performance of the classifi-
cation showed that the AUROC of the classifier for 
advanced NASH versus healthy controls was 0.77 
(UB2L3 > Fas, soluble pair) and showed a good sep-
aration between advanced NASH and healthy con-
trols (blue squares assigned to healthy controls, red 
squares assigned to advanced NASH) with sensitiv-
ity of 75%, specificity of 83%, and accuracy of 77% 
(Fig. 5B). For the precirrhotic NASH versus cirrhotic 
NASH comparison, the best accuracy was achieved 
by two feature pairs (IL13Ra1 > TNR4; WISP-1 
> BMP-14) and showed an accuracy of 80%, sen-
sitivity of 80%, and specificity of 80% (Fig. 5D). 
These protein pair(s) have strong predictive power 
for liver fibrosis or cirrhosis disease classification, 
and confirmatory studies by other protein assay plat-
forms in additional data sets will help to validate 
our findings. To further strengthen our findings, we 
decided to adopt a multibiomarker approach consist-
ing of identifying a panel of EV-encapsulated pro-
teins that may be used as disease-specific signatures 
to diagnose advanced NASH. Specifically, we per-
formed an independent validation study by repeat-
ing the SOMAscan protein array on a new group of 
10 randomly selected circulating EV samples from 
precirrhotic NASH and cirrhotic NASH and 6 from 
healthy controls. Using statistical pairwise compari-
sons, we assessed the validity of identified circulat-
ing EV protein signatures by authenticating their 
correlation with histological assessment of advanced 
NASH. Expression levels of the top seven most 
expressed circulating EV proteins in cirrhotic NASH 
samples (WISP1 [Wnt1-inducible signaling pathway 
protein-1], aminoacyl-tRNA synthetase interacting 
multifunctional protein 1 [AIMP1], IL27RA [inter-
leukin-27RA], ICAM2 [intercellular cell adhesion 
molecule 2], IL1β [interleukin-1β], STK16 [serine/
threonine protein kinase], and RGMA [repulsive 
guidance molecule A precursor]) were compared in 
precirrhotic NASH versus healthy controls, cirrhotic 
NASH versus healthy controls, and cirrhotic NASH 
versus precirrhotic NASH. Interestingly, our anal-
yses show a clear separation in distribution of all 
seven proteins, particularly in the cirrhotic NASH 
versus healthy controls and in cirrhotic NASH 
versus precirrhotic NASH cohort comparisons 
(Fig. 6A-G). Among all comparisons, the distribu-
tion of some proteins separated particularly well in 
the two cohorts. These include WISP1, with a FC of 
1.26 in cirrhotic NASH versus healthy controls and 
1.32 in cirrhotic NASH versus precirrhotic NASH 
(Fig. 6A); AIMP1, with a FC of 1.24 in cirrhotic 
NASH versus healthy controls and 1.12 in cirrhotic 
NASH versus precirrhotic NASH (Fig. 6B); and 
IL27RA, with a FC of 1.23 in cirrhotic NASH ver-
sus healthy controls and 1.14 in cirrhotic NASH 
versus precirrhotic NASH (Fig. 6C). Our findings 
confirm that protein EV–based signatures may have 
utility as tools to diagnose patients with NASH.
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Discussion
The findings of this study show that circulating 
EVs can be isolated and characterized from the serum 
samples of patients with different stages of NASH. 
EVs are membrane-surrounded structures potentially 
released from every cell in the extracellular environ-
ment. Based on their biogenesis, composition and size, 
EVs can be classified as small vesicles or exosomes 
(30-150 nm in diameter), which are released by exo-
cytosis following fusion of multivesicular bodies with 
the plasma membrane, and large vesicles or microve-
sicles (150-1,000 nm in diameter), which are released 
by controlled budding of the plasma membrane.(28) In 
general, EVs can serve autocrine and paracrine func-
tions by shuttling a variety of bioactive molecules, 
including noncoding RNAs, proteins, lipids, and 
nuclei acids.(29) Although previous studies reported 
Fig. 5. Performance of circulating EV protein signatures for identification of healthy controls, patients with precirrhotic NASH, or 
patients with cirrhotic NASH. (A) kTSP votes training heat map of the k-top performing pairs of circulating EV proteins identified 
in patients with advanced NASH versus healthy controls during the validation study. The 20 gray boxes correspond to 10 patients with 
precirrhotic NASH and 10 patients with cirrhotic NASH grouped into one advanced NASH data set, while the red boxes correspond to 
the 6 healthy controls. (B) AUROC of kTSP-selected top performing pairs of circulating EV proteins identified in patients with advanced 
NASH versus healthy controls (AUROC: 0.77; 95% CI: 0.5635-0.9103). (C) kTSP votes training heat map of the top performing pairs 
of circulating EV proteins identified in patients with precirrhotic NASH versus patients with cirrhotic NASH during the validation 
study. Gray and red boxes correspond to each of the 10 patients in the two groups. (D) AUROC of kTSP-selected top performing pairs 
of circulating EV proteins identified in patients with precirrhotic NASH versus patients with cirrhotic NASH (AUROC: 0.8; 95% CI: 
0.5634-0.9427). A cutoff value equal to the number of kTPS pairs observed in each group was adopted.
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the levels of immune cell-derived EVs in patients 
with NASH,(30) we used an unbiased approach and 
characterized total circulating EVs as well as EVs 
derived from hepatocytes, as they represent the most 
abundant cell in the liver and are particularly affected 
by lipid-induced toxicity.(30) More recent studies on 
patient cohorts provided insights on the bioavailabil-
ity of circulating EVs in various biofluids and, as a 
consequence, on their potential use as biomarkers for 
various diseases such as cancer,(10,21) cardiovascular 
diseases,(31) renal disease(20) and liver disease.(30,32) 
However, studies that investigate the EV dynam-
ics, protein cargo, and performance as potential bio-
markers in well-characterized and liver biopsy-proven 
cohorts of patients with NASH are currently not 
available.(13,16) For this reason, we isolated circulating 
EVs from a well-characterized cohort of patients with 
histologically confirmed advanced NASH-associated 
fibrosis. Considering the heterogeneity of circulating 
EVs and challenges of EV isolation from biofluids, 
we performed a full characterization of our EV sam-
ples, including physical and molecular assessments, to 
provide evidence on the properties of our EV popula-
tion and confirm the presence of EVs in our samples 
before any further analysis of EV quantity and cargo. 
Physical and molecular characterization of EVs iden-
tified elevated levels of circulating EVs in advanced 
NASH samples compared with healthy controls. 
Isolated circulating EVs expressed common EV mark-
ers, such as Alix, TSG101 and CD63, and elicit sim-
ilar size. Several studies have shown that circulating 
EVs shuttle bioactive molecules from the parental cell 
or tissue of origin, and liver cells are not an exception. 
Hepatocytes, like all other liver cells, produce and 
release EVs,(33-35) which contain hepatocyte markers 
ASGPR1 and SLC27A5.(13,36) Based on these results, 
measurement of hepatocyte-derived circulating EVs 
may be a more sensitive, robust, and disease-specific 
approach than measuring total EVs. We indeed con-
firmed that approximately 20% of total circulating EVs 
derive from hepatocytes and that ASGPR1-positive, 
but not SLC27A5-positive, hepatocyte-specific EV 
amount progressively increases with disease severity 
and significantly correlates with clinical characteris-
tics of NASH, including fibrosis stage, noninvasive 
markers of fibrosis (e.g., ELF test, FibroTest, NAFLD 
Fibrosis Score), bilirubin, platelet count, and HVPG. 
The worse correlation of SLC27A5-positive EVs 
and NASH/cirrhosis may be associated with fat loss 
during transition to cirrhosis and lower hepatocyte 
specificity of this enzyme, which is expressed in other 
extrahepatic tissues, such as lungs and gallbladder. 
Notably, ASGPR1+ hepatocyte EVs significantly cor-
related with HVPG, a variable of established assess-
ment of portal hypertension, and were able to reliably 
identify patients with HVPG of 10 mmHg or higher, 
which has been identified has the clinically significant 
threshold for the diagnosis of portal hypertension. 
An elegant study by Payancé et al.(37) also reported a 
correlation between hepatocyte-derived EV (defined 
based on the presence of cytokeratin-18 within EVs) 
levels with HVPG. Our results provide further evi-
dence that ASGPR1+ hepatocyte-specific EVs may 
represent a surrogate noninvasive biomarker of por-
tal hypertension in patients with cirrhotic NASH. If 
confirmed, these findings may support clinical utility 
of ASGPR1-positive EVs as potential alternative to 
invasive HVPG. A major hurdle in translating bio-
marker research studies into clinically useful assays is a 
lack of reproducibility and rigorous criteria for report-
ing of potential NASH biomarkers. For this study, we 
adopted a multimarker approach by identifying and 
validating statistically a manageable number of EV 
proteins that can provide higher sensitivity and spec-
ificity than individual markers. Analysis of the circu-
lating EV protein cargo in each study group identified 
unique protein signatures that were validated and that 
carry strong prognostic power, particularly to separate 
healthy controls and patients with precirrhotic NASH 
from patients with cirrhotic NASH. Unfortunately, 
independent proteomics analysis of EVs isolated from 
patients with advanced NASH are currently limited 
Fig. 6. Pairwise comparisons of different levels of circulating EV proteins in a validation cohort of patients with cirrhotic NASH, patients 
with precirrhotic NASH, and healthy controls. Boxplots of pairwise comparisons of the top seven highest expressed circulating EV 
proteins isolated from patients with cirrhotic NASH, patients with precirrhotic NASH, and healthy controls. Data are reported as log2FC 
for WISP1 (A), AIMP1 (B), IL27RA (C), ICAM2 (D), IL1β (E), STK16 (F), and RGMA (G) for the three comparisons: patients 
with precirrhotic NASH versus healthy controls (left), patients with cirrhotic NASH versus healthy controls (center), and patients with 
precirrhotic NASH versus patients with cirrhotic NASH (right). Wilcoxon test (nonparametric, comparing the distributions of pairwise 
cohorts) and a regular Student t test (comparing means of raw and log2 values) were used to generate the P values reported in the boxplots.
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or not available. However, proteomics analysis of EVs 
isolated from experimental murine models of NASH 
reported similar signatures or single analytes that were 
also found in our report. Larger and additional studies 
will be required to confirm our findings. An important 
element for our study was to avoid any potential con-
tamination of plasma proteins or lipoproteins in our 
EV samples. Therefore, for EV isolation, we combined 
differential centrifugation with size-exclusion chroma-
tography, which has been shown to provide purer EV 
samples.(22) Interestingly, our proteomics array, which 
included over 1,300 unique analytes, identified a large 
number of proteins differentially expressed in EVs 
from healthy individuals, patients with precirrhotic 
NASH, and patients with cirrhotic NASH, suggest-
ing that protein cargo of circulating EVs is unique for 
each NASH stage and that these stage-specific pro-
tein signatures may have utility as liquid biopsies for 
diagnosis of patients with NASH. To further improve 
the robustness of our findings, we conducted extensive 
validation analyses using an extension of the kTSP to 
develop understandable and powerful EV-based pro-
teomics signatures. Our analysis showed that selected 
protein pairs warrant strong predictive power not 
only for advanced NASH but also for differentiating 
precirrhotic and cirrhotic NASH. Additional statisti-
cal authentication of our data confirmed associations 
between identified circulating EV protein signa-
tures with precirrhotic and cirrhotic NASH samples. 
Specifically, pair-wise comparisons showed that EV 
proteins such as WISP1, AIMP1, IL27RA, ICAM2, 
IL1β, STK16, and RGMA can reliably differenti-
ate healthy controls from patients with precirrhotic 
and cirrhotic NASH. Although the specific roles of 
these proteins in the progression of NASH are not 
fully understood, it is known that they are involved 
in processes relevant to NASH progression, such as 
inflammation (IL1β, AIMP1, IL27RA, ICAM2), 
cell death (WISP1), wound healing (AIMP1), vesi-
cle trafficking, and the transforming growth factor β/
SMAD signaling pathway (STK16, RGMA). Despite 
the statistically powerful performance of the identi-
fied EV-protein signatures in discriminating healthy 
individuals from individuals with advanced NASH 
or patients with precirrhotic NASH from cirrhotic 
NASH, these results will require validation by inde-
pendent groups. In addition, further studies in cohorts 
including patients with early NASH and isolated fatty 
liver, as well as non-NASH liver disease controls, will 
provide important information regarding the utility of 
EV assessment for distinguishing the full spectrum of 
patients with NAFLD.
Study Limitations
The limitations of this study include the relatively 
low number of samples analyzed and the lack of sam-
ples from patients with early NASH. This is also 
reflected in the relatively large confidence intervals of 
the AUROC analyses found in the proteomic-based 
studies. Future validation using larger number of 
patient samples are therefore needed to confirm the 
EV-protein signatures identified in our study utility as 
a NASH liquid biopsy.
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